Alkermes Inc. plc (ALKS)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Alkermes Inc. plc (ALKS)
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Key Insights
Critical company metrics and information
Share Price
$31.46Market Cap
$5.09 BillionTotal Outstanding Shares
161.80 Million SharesTotal Employees
2,100Dividend
No dividendIPO Date
July 16, 1991SIC Description
Pharmaceutical PreparationsHomepage
https://www.alkermes.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities, Continuing | $-118.42 Million |
Net Cash Flow From Financing Activities | $-488.97 Million |
Net Cash Flow From Investing Activities | $-118.42 Million |
Net Cash Flow From Financing Activities, Continuing | $-488.97 Million |
Net Cash Flow From Operating Activities, Continuing | $355.96 Million |
Net Cash Flow, Continuing | $-251.42 Million |
Net Cash Flow | $-251.42 Million |
Net Cash Flow From Operating Activities | $355.96 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Revenues | $1.51 Billion |
Income/Loss From Discontinued Operations Net Of Tax | $-53.61 Million |
Diluted Earnings Per Share | $1.98 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Net Income/Loss | $333.35 Million |
Other Operating Expenses | $10.08 Million |
Selling, General, and Administrative Expenses | $668.03 Million |
Operating Income/Loss | $312.58 Million |
Cost Of Revenue | $253.34 Million |
Benefits Costs and Expenses | $1.17 Billion |
Net Income/Loss Available To Common Stockholders, Basic | $333.35 Million |
Nonoperating Income/Loss | $19.60 Million |
Basic Average Shares | $331.75 Million |
Costs And Expenses | $1.19 Billion |
Income/Loss From Continuing Operations Before Tax | $332.18 Million |
Net Income/Loss Attributable To Parent | $333.35 Million |
Operating Expenses | $939.20 Million |
Income/Loss From Continuing Operations After Tax | $386.95 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Income Tax Expense/Benefit | $-54.78 Million |
Basic Earnings Per Share | $2.01 |
Research and Development | $261.08 Million |
Gross Profit | $1.25 Billion |
Diluted Average Shares | $337.73 Million |
Income Tax Expense/Benefit, Deferred | $-20.20 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Noncurrent Assets | $591.11 Million |
Equity | $1.29 Billion |
Current Liabilities | $453.70 Million |
Equity Attributable To Parent | $1.29 Billion |
Current Assets | $1.56 Billion |
Other Current Assets | $1.01 Billion |
Noncurrent Liabilities | $409.48 Million |
Inventory | $191.09 Million |
Liabilities | $863.18 Million |
Assets | $2.16 Billion |
Fixed Assets | $225.42 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Wages | $55.90 Million |
Accounts Receivable | $367.21 Million |
Liabilities And Equity | $2.16 Billion |
Other Non-current Assets | $365.69 Million |
Accounts Payable | $37.04 Million |
Other Current Liabilities | $360.76 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Related Companies
View additional S&P 500 companies similar to Alkermes Inc. plc (ALKS)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.